Cureworth Drugs & Intermediates Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.00 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 13.05 Cr
- Satisfied Charges ₹ 10.84 Cr
- Revenue Growth -41.68%
- Profit Growth -69.03%
- Ebitda -45.71%
- Net Worth 6.23%
- Total Assets -4.88%
About Cureworth Drugs & Intermediates
Cureworth Drugs & Intermediates Private Limited (CDIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 June 2010 and has a history of 14 years and seven months. Its registered office is in Raigarh, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹13.05 Cr. The company has closed loans amounting to ₹10.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anjana Nishad and Ramchandra Nishad serve as directors at the Company.
Company Details
-
Location
Raigarh, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232MH2010PTC204157
-
Company No.
204157
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Jun 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Cureworth Drugs & Intermediates Private Limited offer?
Cureworth Drugs & Intermediates Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, API Intermediate, Common Disease Medicines, Allopathic Cough Syrup, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Cureworth Drugs & Intermediates?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjana Nishad
|
Director | 15-Jun-2010 | Current |
|
Ramchandra Nishad
|
Director | 14-Jun-2010 | Current |
Financial Performance of Cureworth Drugs & Intermediates.
Cureworth Drugs & Intermediates Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 41.68% decrease. The company also saw a substantial fall in profitability, with a 69.03% decrease in profit. The company's net worth moved up by a moderate rise of 6.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cureworth Drugs & Intermediates?
In 2022, Cureworth Drugs & Intermediates had a public holding of 6.35%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Anuj Engineers (I) Private LimitedAnjana Nishad and Ramchandra Nishad are mutual person
-
Anjani Chem Pharma Private Limited
Ramchandra Nishad is a mutual person
Charges (Loans)
₹130.50 M
₹108.43 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 13.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2023 | Hdfc Bank Limited | ₹6.45 Cr | Open |
| 24 Mar 2023 | Hdfc Bank Limited | ₹6.60 Cr | Open |
| 28 Jun 2021 | Bank Of India | ₹2.50 Cr | Satisfied |
| 07 Apr 2021 | Bank Of India | ₹2.40 M | Satisfied |
| 01 Aug 2017 | Bank Of India | ₹8.23 M | Satisfied |
How Many Employees Work at Cureworth Drugs & Intermediates?
Cureworth Drugs & Intermediates has a workforce of 39 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cureworth Drugs & Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cureworth Drugs & Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
